Published in Blood on December 30, 2004
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest (2010) 1.53
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther (2009) 1.40
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 1.37
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res (2015) 1.17
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res (2011) 1.15
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One (2013) 1.08
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther (2014) 0.99
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med (2013) 0.89
CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. Clin Exp Immunol (2006) 0.88
Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther (2014) 0.87
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunol Res (2015) 0.86
Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLoS One (2013) 0.84
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med (2005) 0.84
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget (2015) 0.83
From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. Hum Gene Ther (2014) 0.79
Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer. Oncotarget (2011) 0.78
NKG2D⁺ IFN-γ⁺ CD8⁺ T cells are responsible for palladium allergy. PLoS One (2014) 0.76
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest (2004) 1.70
Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood (2011) 1.69
Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology (2008) 1.61
Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res (2002) 1.40
Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer (2003) 1.19
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res (2006) 1.18
Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res (2004) 1.15
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
Growth inhibition of prostate cancer xenografts by halofuginone. Prostate (2002) 1.07
Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia (2004) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res (2003) 1.01
Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. Prostate (2008) 0.97
Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology (2009) 0.97
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology (2012) 0.94
Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem (2002) 0.94
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther (2014) 0.92
Quantitative detection of protein arrays. Anal Chem (2003) 0.88
Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate (2009) 0.87
Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis. J Mol Biol (2002) 0.86
Designing prehospital ECG systems for acute coronary syndromes. Lessons learned from clinical trials involving 12-lead ST-segment monitoring. J Electrocardiol (2005) 0.86
The emergence of T-bodies/CAR T cells. Cancer J (2014) 0.83
Synthetic secondary chromosomes in Escherichia coli based on the replication origin of chromosome II in Vibrio cholerae. Biotechnol J (2014) 0.82
Suppression subtractive hybridization and comparative expression analysis to identify developmentally regulated genes in filamentous fungi. J Basic Microbiol (2012) 0.78
The histone chaperone ASF1 is essential for sexual development in the filamentous fungus Sordaria macrospora. Mol Microbiol (2012) 0.78
Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer. Oncotarget (2011) 0.78
Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions. Nano Lett (2012) 0.77
Tumor-specific allogeneic cells for cancer therapy. Expert Opin Biol Ther (2011) 0.77
CAR's made it to the pancreas. Oncoimmunology (2012) 0.75
Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells. Discov Med (2005) 0.75
Electrically controlled molecular recognition harnessed to activate a cellular response. Nano Lett (2011) 0.75
Opinion paper on the current status of the regulation of gene therapy in Europe. Hum Gene Ther (2002) 0.75